Status:
UNKNOWN
Prophylactic Vs. Therapeutic Use of Uroxatrol in Men Undergoing Brachytherapy
Lead Sponsor:
New York Prostate Institute
Collaborating Sponsors:
Sanofi
Conditions:
Prostate Cancer
Eligibility:
MALE
Phase:
PHASE3
Brief Summary
To asess the efficacy of Uroxatrol, an alpha blocker in men undergoing prostate brachytherapy to treat prostate cancer, and whether the use of Uroxatrol in advance of the brachytherapy is better or no...
Detailed Description
Prostate brachytherapy is an increasingly popular method of treating clinically localized prostate cancer. The major morbidity of this procedure is obstructive and irritative voiding symptoms. The ris...
Eligibility Criteria
Inclusion
- 1\) Informed consent must be obtained. 2) Men of any age 3) Diagnosis of prostate cancer that is clinically localized 4) Patients must be eligible for permanent prostate brachytherapy either alone or with combination of other treatments (i.e. External beam radiation or hormonal therapy)
Exclusion
- Refusal to participate in the study
- Prior use of alpha-blocker or anti-cholinergic medication in the treatment of prostate hypertrophy.
- Contraindication to using an alpha-blocker
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00201630
Start Date
September 1 2005
End Date
September 1 2005
Last Update
September 20 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York Prostate Institute
Oceanside, New York, United States, 11572